Viracta Therapeutics Inc
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trial… Read more
Market Cap & Net Worth: Viracta Therapeutics Inc (VIRX)
Viracta Therapeutics Inc (NASDAQ:VIRX) has a market capitalization of $874.37K ($874.37K) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #37331 globally and #12156 in its home market, demonstrating a -19.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viracta Therapeutics Inc's stock price $0.02 by its total outstanding shares 39744200 (39.74 Million).
Viracta Therapeutics Inc Market Cap History: 2015 to 2025
Viracta Therapeutics Inc's market capitalization history from 2015 to 2025. Data shows change from $7.53 Billion to $874.37K (-61.69% CAGR).
Viracta Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viracta Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2312.62x
Viracta Therapeutics Inc's market cap is 2312.62 times its annual revenue
1728.56x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $7.53 Billion | $3.06 Million | -$37.62 Million | 2460.14x | N/A |
| 2016 | $5.05 Billion | $2.54 Million | -$39.74 Million | 1990.62x | N/A |
| 2017 | $5.15 Billion | $669.00K | -$36.85 Million | 7691.82x | N/A |
| 2018 | $585.70 Million | $237.00K | -$27.77 Million | 2471.32x | N/A |
| 2019 | $474.14 Million | $2.07 Million | -$23.33 Million | 228.72x | N/A |
| 2020 | $277.51 Million | $120.00K | -$19.20 Million | 2312.62x | N/A |
Competitor Companies of VIRX by Market Capitalization
Companies near Viracta Therapeutics Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Viracta Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Viracta Therapeutics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Viracta Therapeutics Inc's market cap moved from $7.53 Billion to $ 874.37K, with a yearly change of -61.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $874.37K | -86.33% |
| 2024 | $6.39 Million | -71.77% |
| 2023 | $22.65 Million | -60.96% |
| 2022 | $58.03 Million | -60.00% |
| 2021 | $145.07 Million | -47.73% |
| 2020 | $277.51 Million | -41.47% |
| 2019 | $474.14 Million | -19.05% |
| 2018 | $585.70 Million | -88.62% |
| 2017 | $5.15 Billion | +1.93% |
| 2016 | $5.05 Billion | -32.96% |
| 2015 | $7.53 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Viracta Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $874.37K USD |
| MoneyControl | $874.37K USD |
| MarketWatch | $874.37K USD |
| marketcap.company | $874.37K USD |
| Reuters | $874.37K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.